Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05212597
Other study ID # reverseAR
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date January 12, 2022
Est. completion date December 2024

Study information

Verified date January 2022
Source Samsung Medical Center
Contact Eun Kyoung Kim, MD. PhD
Phone 82-2-3410-3419
Email ekbobi.kim@samsung.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the efficacy of sacubitril-valsartan compared to the combination of ARB/CCB on left ventricular remodeling in patients with chronic aortic valve regurgitation.


Description:

After being informed consent about the study and potential risk, all patients giving written informed consent will undergo a 1 month screening period to determine eligibility for study entry. At week 0, patients who meet the eligibility requirements will be randomized in an open-label manner in a 1:1 ratio to sacubitril-valsartan or amlodipine/losartan.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 2024
Est. primary completion date December 2023
Accepts healthy volunteers No
Gender All
Age group 20 Years to 90 Years
Eligibility Inclusion Criteria: 1. Participant over 20 years of age who has not been hospitalized for heart failure 2. Participant with hypertension or systolic blood pressure 125 mmHg or higher 3. NYHA I 4. Participant with chronic severe aortic regurgitation (VCW >0.6cm) 5. Participant with AV regurgitant volume = 60mL or effective regurgitant orifice area = 0.3 cm2 6. Participant with left ventricular ejection fraction = 55% Exclusion Criteria: 1. A history of hypersensitivity or allergy to clinical trial drugs or similar compounds or ARB/NEP inhibitors 2. History of angioedema 3. Patients with an ascending aorta dilated by more than 55 mm 4. Patients with aortic valve insufficiency due to hereditary aortic disease (Marfan syndrome, Ehlers-Danlos syndrome) 5. Patients with moderate to severe aortic stenosis 6. Patients with claustrophobia or with metallic implants unsuitable for magnetic resonance imaging 7. History of acute heart failure within 6 weeks and dyspnea of NYHA II or higher 8. Symptomatic hypotension or SBP < 100 mmHg at screening 9. Patients with renal failure (Estimated GFR < 30 mL/min/1.73 m2) or on dialysis 10. Significant increase in blood potassium level (Potassium > 5 mmol/L) 11. Blood AST or ALT value is more than twice the upper limit of normal or symptoms and signs of cirrhosis (history of hepatic coma, history of esophageal varices, history of symptomatic ascites) 12. In case of acute coronary syndrome, stroke, thoracic surgery, and percutaneous coronary angioplasty within 3 months 13. If aortic valve surgery is scheduled within the next 6 months 14. In case of severe mitral valve disease 15. Patients with primary hyperaldosteronism 16. If a woman of childbearing potential has not used double contraception 17. Women who are currently pregnant or lactating 18. When it is judged that there are clinically significant abnormalities in physical examination, diagnostic examination, electrocardiogram, etc. at the time of the screening visit

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Sacubitril-valsartan
50mg~100mg twice daily
Amlodipine-losartan
amlodipine/losartan 2.5/25mg ~ 5/100mg once daily

Locations

Country Name City State
Korea, Republic of Samsung Medical Center Seoul

Sponsors (1)

Lead Sponsor Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of left ventricular end-diastolic volume index from baseline to 12 months follow-up Change = [LVEDV on CMR at 12 months]-[LVEDV on CMR at baseline] Baseline and month 12
Secondary Change of regurgitant volume of aortic valve regurgitation from baseline to 12 months follow-up. Change = [regurgitant volume at 12 months]-[regurgitant volume at baseline] Baseline and month 12
Secondary Change of EROA of aortic valve regurgitation from baseline to 12 months follow-up. Measurement of regurgitant volume of AR is derived from Doppler imaging on echocardiography.
Change = [regurgitant volume at 12 months]-[regurgitant volume at baseline]
Baseline and month 12
Secondary Change of LV end-systolic volume from baseline to 12 months follow-up. Change = [LVEDV at 12 months]-[LVEDV at baseline] Baseline and month 12
Secondary Holodiastolic flow reversal in the proximal abdominal aorta and descending thoracic aorta from baseline to 12 months follow-up presence or absence of holodiastolic flow reversal in the proximal abdominal and descending thoracic aorta on echocardiography Baseline and month 12
Secondary Change of NT-proBNP level from baseline to 12 months follow-up. Change =[NT-proBNP at 12 months]-[NTproBNP at baseline] Baseline and month 12
Secondary Aortic valve replacement or repair operation Any surgical event for correction of AR During 12 months after enrollment
See also
  Status Clinical Trial Phase
Recruiting NCT04149600 - Identification of Genetic Causes of Calcific Aortic Valve Disease
Enrolling by invitation NCT04035356 - HAART Annuloplasty Device Valve Repair Registry
Unknown status NCT01201070 - Study of Administration Of Antithrombin in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery Phase 4
Active, not recruiting NCT04281771 - Assessment of Paravalvular Leak After TAVI by Hemodynamic Measurements and Cardiac MRI N/A
Completed NCT03644784 - Protocoled Quantitative Assessment of Aortic Regurgitation Using Videodensitometry in a Multicontinental Trial in Rotterdam, Montreal, Yamaguchi, Segeberg, Amsterdam.
Recruiting NCT02288871 - Pilot Trial: Comparison of Flow Patterns N/A
Completed NCT01651780 - Open-label, Randomized Trial in Patients Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH Phase 3
Completed NCT01171625 - Carpentier-Edwards PERIMOUNT Magna Ease Pericardial Bioprosthesis, Model 3300TFX N/A
Terminated NCT00598598 - Echocardiographic Assessment of Cardiovascular Changes in Long Term Space Flight N/A
Recruiting NCT05295628 - Evaluation of Safety and Effectiveness of the EMBLOK EPS During TAVR N/A
Recruiting NCT06034028 - J-Valve TF Early Feasibility Study N/A
Recruiting NCT06295068 - Evaluation of ARi With OpSens SavvyWire
Completed NCT05742789 - Effect of Anesthetics on Troponin I and С-reactive Protein Phase 1
Recruiting NCT05172973 - ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves N/A
Completed NCT00727181 - An Observational, Prospective Evaluation of the Trifecta™ Valve N/A
Active, not recruiting NCT04415047 - The JenaValve ALIGN-AR Pivotal Trial N/A
Not yet recruiting NCT02623907 - China Valve Registry Study-1 N/A
Completed NCT00475267 - Aortic Valve Replacement With Trifecta(TM) N/A
Completed NCT00478803 - Conservative Aortic Valve Surgery for Aortic Insufficiency and Aneurysms of the Aortic Root. CAVIAAR Phase 3
Completed NCT00001314 - Investigation of Heart Function in Patients With Heart Valve Defects N/A